4D Molecular Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.785
- Today's High:
- $16.445
- Open Price:
- $16.15
- 52W Low:
- $5.32
- 52W High:
- $26.49
- Prev. Close:
- $15.89
- Volume:
- 272490
Company Statistics
- Market Cap.:
- $785.31 million
- Book Value:
- 6.577
- Revenue TTM:
- $2.21 million
- Operating Margin TTM:
- -5151.54%
- Gross Profit TTM:
- $-77124000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.99%
- Return on Equity TTM:
- -42.68%
Company Profile
4D Molecular Therapeutics Inc had its IPO on 2020-12-11 under the ticker symbol FDMT.
The company operates in the Healthcare sector and Biotechnology industry. 4D Molecular Therapeutics Inc has a staff strength of 137 employees.
Stock update
Shares of 4D Molecular Therapeutics Inc opened at $16.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.79 - $16.45, and closed at $16.06.
This is a +1.07% increase from the previous day's closing price.
A total volume of 272,490 shares were traded at the close of the day’s session.
In the last one week, shares of 4D Molecular Therapeutics Inc have slipped by -3.02%.
4D Molecular Therapeutics Inc's Key Ratios
4D Molecular Therapeutics Inc has a market cap of $785.31 million, indicating a price to book ratio of 3.0145 and a price to sales ratio of 378.8959.
In the last 12-months 4D Molecular Therapeutics Inc’s revenue was $2.21 million with a gross profit of $-77124000 and an EBITDA of $-110720000. The EBITDA ratio measures 4D Molecular Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, 4D Molecular Therapeutics Inc’s operating margin was -5151.54% while its return on assets stood at -24.99% with a return of equity of -42.68%.
In Q1, 4D Molecular Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 75.6%.
4D Molecular Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 4D Molecular Therapeutics Inc’s profitability.
4D Molecular Therapeutics Inc stock is trading at a EV to sales ratio of 277.0105 and a EV to EBITDA ratio of -5.3185. Its price to sales ratio in the trailing 12-months stood at 378.8959.
4D Molecular Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $244.02 million
- Total Liabilities
- $11.28 million
- Operating Cash Flow
- $43.13 million
- Capital Expenditure
- $1.01 million
- Dividend Payout Ratio
- 0%
4D Molecular Therapeutics Inc ended 2024 with $244.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $244.02 million while shareholder equity stood at $-343172000.00.
4D Molecular Therapeutics Inc ended 2024 with $219000.00 in deferred long-term liabilities, $11.28 million in other current liabilities, 3000.00 in common stock, $-343172000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $201.86 million and cash and short-term investments were $201.86 million. The company’s total short-term debt was $2,678,000 while long-term debt stood at $0.
4D Molecular Therapeutics Inc’s total current assets stands at $207.04 million while long-term investments were $1.41 million and short-term investments were $121.89 million. Its net receivables were $0 compared to accounts payable of $2.41 million and inventory worth $0.
In 2024, 4D Molecular Therapeutics Inc's operating cash flow was $43.13 million while its capital expenditure stood at $1.01 million.
Comparatively, 4D Molecular Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $16.06
- 52-Week High
- $26.49
- 52-Week Low
- $5.32
- Analyst Target Price
- $38.43
4D Molecular Therapeutics Inc stock is currently trading at $16.06 per share. It touched a 52-week high of $26.49 and a 52-week low of $26.49. Analysts tracking the stock have a 12-month average target price of $38.43.
Its 50-day moving average was $17.37 and 200-day moving average was $19.03 The short ratio stood at 3.76 indicating a short percent outstanding of 0%.
Around 976.9% of the company’s stock are held by insiders while 8616.3% are held by institutions.
Frequently Asked Questions About 4D Molecular Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.